Loading...
XHKG
9997
Market cap1.38bUSD
Nov 11, Last price  
9.20HKD
Name

Kangji Medical Holdings Ltd

Chart & Performance

D1W1MN
XHKG:9997 chart
P/E
16.15
P/S
9.31
EPS
0.49
Div Yield, %
16.72%
Shrs. gr., 5y
2.75%
Rev. gr., 5y
14.91%
Revenues
1.01b
+8.92%
247,506,000353,670,000503,467,000511,490,000690,263,000786,367,000926,023,0001,008,610,000
Net income
581m
+15.36%
117,705,000146,701,000206,444,000250,296,000456,789,000478,735,000504,021,000581,438,000
CFO
560m
+33.48%
142,715,000204,737,000325,842,000221,044,000435,749,000319,313,000419,615,000560,098,000
Dividend
May 27, 20250.2613 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kangji Medical Holdings Limited, together with its subsidiary companies, focuses on the entire lifecycle of advanced minimally invasive surgical instruments and their accessories, from initial design and development to manufacturing and sales, primarily serving the Chinese market. The company's extensive product range includes various single-use instruments, such as trocars, polymer ligation clips, electrocoagulation forceps, and ultrasonic scalpels, alongside other disposable hand-held devices. Complementing these are its multi-use offerings, which feature reusable trocars and forceps, among other re-sterilizable products. These specialized tools are utilized across several medical disciplines, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. Kangji Medical primarily distributes its products through an established network of distributors. The company, which has its headquarters in Hangzhou, China, commenced operations in 2004.
IPO date
Jun 29, 2020
Employees
982
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT